Clinical trial awareness gap: behavioral signals before patients find trials
Fewer than 5% of adult cancer patients enroll in clinical trials, yet behavioral data shows patients are searching for trial-related information weeks or months before they ever ask a clinician. The gap between trial awareness and trial discovery is not a marketing problem. It is a data infrastructure problem that behavioral intelligence can close.
Most patients who qualify for a clinical trial never learn one exists. The number is staggering: fewer than 5% of adult cancer patients in the United States enroll in a clinical trial, according to data from the National Cancer Institute. The standard explanation is that patients lack awareness. But that framing is incomplete. Patients are aware something exists. They search for it. They read about it. They circle it in online communities. The problem is that the system designed to connect them to trials cannot see any of this behavior.
Clinical trial awareness data tells one story when measured through traditional enrollment metrics. It tells a completely different story when measured through behavioral signals that precede formal trial discovery.
The awareness gap is not what you think it is
The top-ranking content on clinical trial awareness focuses on public knowledge surveys and educational campaigns. One widely cited study found that lack of clinical trial awareness is a primary barrier to recruitment. Another frames the issue generationally, arguing that Gen Z will force trials to modernize. A third promotes general clinical research education.
All of these miss the behavioral layer.
Patients do not wake up one morning and decide to search for "clinical trials near me." That search is the end of a process, not the beginning. Before a patient types those words, they have already generated dozens of behavioral signals across weeks or months. They searched for their diagnosis. They researched treatment options. They read about side effects. They looked for second opinions. They asked questions in patient communities. They compared survival statistics.
Each of these actions is a data point. Collectively, they form a trail that predicts trial interest long before the patient acts on it.
What trial discovery behavioral signals actually look like
Behavioral signals before trial discovery follow a recognizable pattern across oncology populations. The sequence is not identical for every patient, but the structure repeats.
First, the patient searches for their specific diagnosis, often using the exact language from their pathology report. Searches like "stage 3B non-small cell lung cancer prognosis" or "triple-negative breast cancer recurrence rate" mark the beginning of active information seeking.
Second, the patient moves to treatment-specific research. They compare standard-of-care options. They search for drug names. They look up terms like "immunotherapy vs chemotherapy" or "targeted therapy for KRAS G12C mutation." This phase often overlaps with searches about side effects, which we have documented extensively in our analysis of chemotherapy side effect behavioral intelligence.
Third, the patient begins searching for alternatives. This is the critical inflection point. Searches shift from "what is the standard treatment" to "what else is available" or "new treatments for [cancer type]." Patients in this phase are not yet searching for clinical trials. They are searching for hope that something beyond the current standard exists.
Fourth, the patient encounters the concept of clinical trials, often indirectly. They read an article about a new drug that is "in trials." They see a mention in a patient forum. They hear about it from a caregiver. This is where trial discovery behavioral signals begin, but they are invisible to ClinicalTrials.gov, to trial sponsors, and to oncology practices.
Fifth, the patient searches explicitly for trials. By this point, the window for optimal enrollment may have narrowed. Treatment decisions may already be locked in. The patient may have started a therapy that makes them ineligible.
The timing problem: behavioral signals arrive before clinical systems listen
The behavioral data shows something that enrollment statistics cannot: patients signal trial interest 30 to 90 days before they take clinical action. We documented this pattern in our analysis of how the 2am search window predicts clinical trial enrollment. Late-night searches for treatment alternatives, side effect comparisons, and survival data cluster in the weeks before a patient mentions trials to their oncologist.
This timing gap matters for two reasons.
First, oncologists report that they discuss clinical trials with patients in fewer than 30% of consultations where a trial is available, according to survey data from the American Society of Clinical Oncology. The clinician conversation happens too late, too rarely, or not at all.
Second, eligibility windows are narrow. Many oncology trials require patients to be treatment-naive or to have progressed on exactly one prior line of therapy. A patient who signals trial interest behaviorally at week two but does not reach a trial coordinator until week twelve may have already started a therapy that disqualifies them.
Key statistics
The scale of the clinical trial awareness gap is measurable, and the numbers are specific.
Where oncology trial access intelligence breaks down
The current trial discovery infrastructure has three structural failures.
ClinicalTrials.gov is a registry, not a matching engine. It lists over 450,000 studies. For a newly diagnosed cancer patient searching at 2am, that database is functionally unusable. The inclusion and exclusion criteria are written for investigators, not for patients. The search interface requires medical terminology that patients often do not have. Even when patients find a potentially relevant trial, they cannot determine eligibility without clinical guidance.
Trial matching tools activate too late. Most electronic trial matching systems sit inside the EHR and activate at the point of care. They require a clinician to initiate a query or an order to trigger a match. By design, these tools cannot capture the behavioral signals that occur weeks before the clinical encounter.
Recruitment campaigns target the wrong moment. Trial sponsors spend millions on recruitment advertising. Much of that spend targets patients who are already actively searching for trials. The behavioral data shows that the highest-impact intervention point is earlier, during the "what else is available" phase, when patients are comparing treatment options but have not yet framed their search around clinical trials.
Recent MedPage Today coverage of ongoing COPD trials and management of immune-related adverse events in checkpoint inhibitor therapy illustrates a parallel problem. Clinicians consume trial information through professional channels that are disconnected from patient behavioral data. The information flows are parallel but never converge.
The equity dimension of the awareness gap
The clinical trial awareness gap is not evenly distributed. It tracks closely with health equity failures that VIOLET identifies in behavioral data.
Patients in rural areas show different search patterns than urban patients. They search for trials later in their disease course. They use different terminology. They are more likely to search for travel logistics and financial assistance before they search for trial eligibility. We have documented how geography shapes health data trust in our work on DataSpine and the geography of health risk.
Spanish-speaking patients show a measurably different behavioral trajectory. Recent work highlighted by MedPage Today on integrating clinical pharmacists into primary care for Spanish-speaking adults underscores how language barriers create care gaps. The same dynamic applies to trial discovery. Spanish-language searches for cancer treatment information follow different patterns and arrive at trial-related content later, if at all.
Black patients are enrolled in oncology trials at roughly half the rate of white patients relative to disease incidence. Behavioral data suggests this is not solely a trust problem or an access problem. It is also an information architecture problem. The content and channels through which trial information reaches Black patient communities are structurally different from those that serve white patient populations.
What behavioral intelligence changes about trial recruitment
Traditional trial recruitment operates on a push model: sponsors design campaigns, sites post flyers, coordinators call patients. Behavioral intelligence enables a pull model: identify patients who are already signaling interest and meet them where they are.
This is not theoretical. VIOLET maps behavioral patterns across oncology populations and identifies cohorts that are approaching trial-relevant decision points based on their search behavior, community engagement, and information-seeking patterns.
The practical applications are specific.
Earlier identification of trial-ready patients. When a patient begins searching for "new treatments for HER2-positive breast cancer" or "immunotherapy clinical trials stage 4 lung cancer," that signal can be captured and routed, with appropriate consent governance, to trial coordinators who have open slots. The patient is already motivated. The system just needs to connect the dots.
Content timing optimization. Trial sponsors can deploy educational content at the moment when patients are most receptive, during the "what else is available" phase rather than after they have already committed to a treatment plan.
Site selection informed by demand signals. Behavioral data reveals geographic concentrations of patients who are signaling trial interest. Sponsors can use this data to open sites where demand already exists rather than placing sites based solely on investigator relationships.
Why trial awareness data needs a trust layer
Behavioral data is powerful but fragile. It is easy to misinterpret, easy to misuse, and easy to collect without adequate consent.
A patient searching for "clinical trial side effects" at 3am is in a vulnerable state. Using that behavioral signal to push a targeted ad for a specific trial the next morning would be a consent violation in spirit even if it passed a narrow legal review.
This is why clinical trial awareness data requires the same trust infrastructure as any other health data. Provenance matters: where did this behavioral signal originate, and was it collected with appropriate transparency? Consent matters: did the patient understand how their data would be used? Recency matters: is the signal from this week or from six months ago, when the patient may have already started treatment?
SuperTruth scores every health data record across these dimensions using the Data Trust Index. For behavioral intelligence applied to trial recruitment, this scoring ensures that signals are trustworthy, timely, and ethically sourced before any matching or outreach occurs.
The infrastructure gap that keeps trials under-enrolled
The clinical trial enrollment problem is often framed as an awareness problem. It is actually an infrastructure problem.
The patients are there. They are searching, reading, and signaling interest. The trials are there. ClinicalTrials.gov lists thousands of open studies at any given time. What is missing is the connective tissue: a trust-scored behavioral intelligence layer that captures patient signals, validates them against consent and provenance standards, and routes them to the right trial at the right time.
We described this structural failure in detail in our analysis of why clinical trials have a data supply problem. The patients exist. The infrastructure to connect them does not.
This is not a technology gap. The tools to capture and analyze behavioral signals exist today. It is a trust gap. Until behavioral data is scored for provenance, consent, and recency, no responsible organization can act on it at scale.
From signals to enrollment: what the path forward looks like
Closing the clinical trial awareness gap requires three changes that are structural, not incremental.
First, capture behavioral signals earlier. Stop waiting for patients to search for "clinical trials." Start listening when they search for their diagnosis, their treatment options, and their prognosis. That is where trial interest begins.
Second, score every signal before acting on it. Behavioral data without trust scoring is surveillance. Behavioral data with trust scoring is intelligence. The distinction is not semantic. It determines whether patients trust the system enough to engage.
Third, connect the behavioral layer to the clinical layer. Trial matching tools that sit inside the EHR need to accept inputs from outside the EHR. Patient-generated behavioral data, scored and validated, should inform trial matching alongside lab results and imaging reports.
The oncology trial enrollment crisis is solvable. The data exists. The patients are signaling. The question is whether the infrastructure will be built to listen.
VIOLET maps behavioral signals across 750+ oncology search terms before patients reach a clinic. If your team is working on cohort identification, trial recruitment timing, or oncology market intelligence for clinical trial enrollment, contact Louis Simeonidis at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.